Vitamin D deficiency and incident stroke risk in community-living black and white adults

International Journal of Stroke

Volumn 11, Issue 1, 2016, Pages 93-102

  Judd, Suzanne E ^a   Morgan, Charity J ^a   Panwar, Bhupesh ^b   Howard, Virginia J ^a   Wadley, Virginia G ^b   Jenny, Nancy S ^c   Kissela, Brett M ^d   Gutiérrez, Orlando M ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

epidemiology; Stroke; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BLACK PERSON; BLOOD PRESSURE; BODY MASS; BRAIN HEMORRHAGE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMMUNITY LIVING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; SOCIAL STATUS; SUBARACHNOID HEMORRHAGE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WAIST CIRCUMFERENCE; AFRICAN AMERICAN; EPIDEMIOLOGY; ETHNOLOGY; MULTIVARIATE ANALYSIS; RISK FACTOR; UNITED STATES;

AFRICAN AMERICANS; AGED; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SEX FACTORS; STROKE; UNITED STATES; VITAMIN D DEFICIENCY;

EID: 84953410480     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1177/1747493015607515     Document Type: Article

References (41)

1. Forman JP, Giovannucci E, Holmes MD. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063-1069.
2. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008; 57: 2619-2625.
3. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2008; 87: 136-141.
4. Martins D, Wolf M, Pan D. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007; 167: 1159-1165.
5. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
6. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
7. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003; 17: 509-511.
8. Zella JB, McCary LC, DeLuca HF. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 2003; 417: 77-80.
9. Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984; 74: 657-661.
10. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995; 125(6 Suppl): 1704S-1748S.
11. Brondum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann Neurol 2013; 73: 38-47.
12. Pilz S, Dobnig H, Fischer JE. Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke 2008; 39: 2611-2613.
13. Sun Q, Pan A, Hu FB, Manson JE, Rexrode KM. 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. Stroke 2012; 43: 1470-1477.
14. Howard G, Cushman M, Kissela BM. Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. Stroke 2011; 42: 3369-3375.
15. Howard G, Lackland DT, Kleindorfer DO. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Intern Med 2013; 173: 46-51.
16. Robinson-Cohen C, Hoofnagle AN, Ix JH. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA 2013; 310: 179-188.
17. Michos ED, Reis JP, Post WS. 25-Hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: the NHANES-III linked mortality files. Nutrition 2012; 28: 367-371.
18. Howard VJ, Cushman M, Pulley L. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005; 25: 135-143.
19. Jackson R, Chambless LE, Yang K. Differences between respondents and nonrespondents in a multicenter community-based study vary by gender ethnicity. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. J Clin Epidemiol 1996; 49: 1441-1446.
20. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol 2006; 163: 197-203.
21. Stroke - 1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989; 20: 1407-1431.
22. Adams HPJrBendixen BH, Kappelle LJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
23. Schneider AT, Kissela B, Woo D. Ischemic stroke subtypes: a population-based study of incidence rates among blacks and whites. Stroke 2004; 35: 1552-1556.
24. Wiklund PG, Brown WM, Brott TG. Lack of aggregation of ischemic stroke subtypes within affected sibling pairs. Neurology 2007; 68: 427-431.
25. Stead LG, Gilmore RM, Bellolio MF. Cardioembolic but not other stroke subtypes predict mortality independent of stroke severity at presentation. Stroke Res Treat 2011; 2011: 281496.
26. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52: 1165-1172.
27. Cushman M, Judd SE, Howard VJ. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke 2014; 45: 1646-1650.
28. Soliman EZ, Howard G, Prineas RJ, McClure LA, Howard VJ. Calculating Cornell voltage from nonstandard chest electrode recording site in the Reasons for Geographic And Racial Differences in Stroke study. J Electrocardiol 2010; 43: 209-214.
29. Levey AS, Stevens LA, Schmid CH. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
30. Onland-Moret NC, van der AD, van der Schouw YT. Analysis of case-cohort data: a comparison of different methods. J Clin Epidemiol 2007; 60: 350-355.
31. Tanner RM, Calhoun DA, Bell EK. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013; 8: 1583-1590.
32. Xiang W, Kong J, Chen S. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
33. Vaidya A, Sun B, Larson C, Forman JP, Williams JS. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. J Clin Endocrinol Metab 2012; 97: 2456-2465.
34. Forman JP, Scott JB, Ng K. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension 2013; 61: 779-785.
35. Judd SE, Raiser SN, Kumari M, Tangpricha V. 1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: a pilot feasibility study. J Steroid Biochem Mol Biol 2010; 121: 445-447.
36. Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaei M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a randomized, double-blind, placebo controlled clinical trial. J Nephropathol 2014; 3: 29-33.
37. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633-1637.
38. Wang Y, Chiang YH, Su TP. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000; 39: 873-880.
39. Mao PJ, Zhang C, Tang L. Effect of calcium or vitamin D supplementation on vascular outcomes: a meta-analysis of randomized controlled trials. Int J Cardiol 2013; 169: 106-111.
40. Manson JE, Bassuk SS, Lee IM. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012; 33: 159-171.
41. Powe CE, Evans MK, Wenger J. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991-2000.